PURPOSE: Radionuclide imaging of insulin-like growth factor type 1 receptor (IGF-1R) expression in tumours might be used for selection of patients who would benefit from IGF-1R-targeted therapy. We have previously shown the feasibility of IGF-1R imaging using the Affibody molecule (111)In-DOTA-His(6)-Z(IGF1R:4551). The use of (99m)Tc instead of (111)In should improve sensitivity and resolution of imaging, and reduce the dose burden to patients. We hypothesized that inclusion of a HEHEHE tag instead of a His(6) tag in Z(IGF1R:4551) would permit its convenient purification using IMAC, enable labelling with [(99m)Tc(CO)(3)](+), and improve its biodistribution. METHODS: Z(IGF1R:4551) was expressed with a HEHEHE tag in the N terminus. The resulting (HE)(3)-Z(IGF1R:4551) construct was labelled with [(99m)Tc(CO)(3)](+). Targeting of IGF-1R-expressing cells using [(99m)Tc(CO)(3)](+)-(HE)(3)-Z(IGF1R:4551) was evaluated in vitro and in vivo. RESULTS: (HE)(3)-Z(IGF1R:4551) was stably labelled with (99m)Tc with preserved specific binding to IGF-1R-expressing DU-145 prostate cancer cells in vitro. In mice, [(99m)Tc(CO)(3)](+)-(HE)(3)-Z(IGF1R:4551) accumulated in IGF-1R-expressing organs (pancreas, stomach, lung and salivary gland). [(99m)Tc(CO)(3)](+)-(HE)(3)-Z(IGF1R:4551) demonstrated 3.6-fold lower accumulation in the liver and spleen than (111)In-DOTA-Z(IGF1R:4551). In NMRI nu/nu mice with DU-145 prostate cancer xenografts, the tumour uptake was 1.32 ± 0.11 %ID/g and the tumour-to-blood ratio was 4.4 ± 0.3 at 8 h after injection. The xenografts were visualized using a gamma camera 6 h after injection. CONCLUSION: (99m)Tc(CO)(3)](+)-(HE)(3)-Z(IGF1R:4551) is a promising candidate for visualization of IGF-1R expression in malignant tumours.
PURPOSE: Radionuclide imaging of insulin-like growth factor type 1 receptor (IGF-1R) expression in tumours might be used for selection of patients who would benefit from IGF-1R-targeted therapy. We have previously shown the feasibility of IGF-1R imaging using the Affibody molecule (111)In-DOTA-His(6)-Z(IGF1R:4551). The use of (99m)Tc instead of (111)In should improve sensitivity and resolution of imaging, and reduce the dose burden to patients. We hypothesized that inclusion of a HEHEHE tag instead of a His(6) tag in Z(IGF1R:4551) would permit its convenient purification using IMAC, enable labelling with [(99m)Tc(CO)(3)](+), and improve its biodistribution. METHODS: Z(IGF1R:4551) was expressed with a HEHEHE tag in the N terminus. The resulting (HE)(3)-Z(IGF1R:4551) construct was labelled with [(99m)Tc(CO)(3)](+). Targeting of IGF-1R-expressing cells using [(99m)Tc(CO)(3)](+)-(HE)(3)-Z(IGF1R:4551) was evaluated in vitro and in vivo. RESULTS: (HE)(3)-Z(IGF1R:4551) was stably labelled with (99m)Tc with preserved specific binding to IGF-1R-expressing DU-145 prostate cancer cells in vitro. In mice, [(99m)Tc(CO)(3)](+)-(HE)(3)-Z(IGF1R:4551) accumulated in IGF-1R-expressing organs (pancreas, stomach, lung and salivary gland). [(99m)Tc(CO)(3)](+)-(HE)(3)-Z(IGF1R:4551) demonstrated 3.6-fold lower accumulation in the liver and spleen than (111)In-DOTA-Z(IGF1R:4551). In NMRI nu/nu mice with DU-145 prostate cancer xenografts, the tumour uptake was 1.32 ± 0.11 %ID/g and the tumour-to-blood ratio was 4.4 ± 0.3 at 8 h after injection. The xenografts were visualized using a gamma camera 6 h after injection. CONCLUSION: (99m)Tc(CO)(3)](+)-(HE)(3)-Z(IGF1R:4551) is a promising candidate for visualization of IGF-1R expression in malignant tumours.
Authors: Richard P Baum; Vikas Prasad; Dirk Müller; Christiane Schuchardt; Anna Orlova; Anders Wennborg; Vladimir Tolmachev; Joachim Feldwisch Journal: J Nucl Med Date: 2010-05-19 Impact factor: 10.057
Authors: Emmy D G Fleuren; Yvonne M H Versleijen-Jonkers; Addy C M van de Luijtgaarden; Janneke D M Molkenboer-Kuenen; Sandra Heskamp; Melissa H S Roeffen; Hanneke W M van Laarhoven; Peter J Houghton; Wim J G Oyen; Otto C Boerman; Winette T A van der Graaf Journal: Clin Cancer Res Date: 2011-10-28 Impact factor: 12.531
Authors: Alberto S Pappo; Shreyaskumar R Patel; John Crowley; Denise K Reinke; Klaus-Peter Kuenkele; Sant P Chawla; Guy C Toner; Robert G Maki; Paul A Meyers; Rashmi Chugh; Kristen N Ganjoo; Scott M Schuetze; Heribert Juergens; Michael G Leahy; Birgit Geoerger; Robert S Benjamin; Lee J Helman; Laurence H Baker Journal: J Clin Oncol Date: 2011-10-24 Impact factor: 44.544
Authors: Fei Huang; Warren Hurlburt; Ann Greer; Karen A Reeves; Stephen Hillerman; Han Chang; Joseph Fargnoli; Friedrich Graf Finckenstein; Marco M Gottardis; Joan M Carboni Journal: Cancer Res Date: 2010-08-31 Impact factor: 12.701
Authors: Anna Orlova; Magdalena Malm; Maria Rosestedt; Zohreh Varasteh; Ken Andersson; Ram Kumar Selvaraju; Mohamed Altai; Hadis Honarvar; Joanna Strand; Stefan Ståhl; Vladimir Tolmachev; John Löfblom Journal: Eur J Nucl Med Mol Imaging Date: 2014-03-13 Impact factor: 9.236
Authors: Hao Hong; Tapas R Nayak; Sixiang Shi; Stephen A Graves; Brianne C Fliss; Todd E Barnhart; Weibo Cai Journal: Mol Pharm Date: 2014-09-04 Impact factor: 4.939
Authors: Maria Rosestedt; Ken G Andersson; Bogdan Mitran; Vladimir Tolmachev; John Löfblom; Anna Orlova; Stefan Ståhl Journal: Sci Rep Date: 2015-10-19 Impact factor: 4.379
Authors: Jennifer D Williams; Florian Kampmeier; Adam Badar; Kevin Howland; Margaret S Cooper; Gregory E D Mullen; Philip J Blower Journal: Bioconjug Chem Date: 2020-11-26 Impact factor: 4.774
Authors: Joanna Strand; Hadis Honarvar; Anna Perols; Anna Orlova; Ram Kumar Selvaraju; Amelie Eriksson Karlström; Vladimir Tolmachev Journal: PLoS One Date: 2013-08-01 Impact factor: 3.240